文献速递胸部肿瘤

间皮瘤中BAP1、CDKN2A、MTAP和NF2改变的免疫组成及免疫治疗结局

Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations.
PubMed 文献 · J Thorac Oncol · 2025-06-25

研究对113例胸膜和腹膜间皮瘤进行外显子组和转录组测序及多重免疫荧光,分析BAP1、CDKN2A、MTAP和NF2状态与肿瘤免疫微环境组成及伊匹木单抗联合纳武利尤单抗疗效的关系。MTAP或CDKN2A缺失者免疫细胞普遍减少并以免疫荒漠表型为主;BAP1改变者免疫治疗生存改善,而NF2和CDKN2A改变者生存较短。

要点

  • MTAP或CDKN2A缺失的间皮瘤免疫细胞普遍减少,以免疫荒漠表型为主。
  • BAP1改变者接受伊匹木单抗联合纳武利尤单抗生存改善,NF2和CDKN2A改变者生存较短。
  • 免疫浸润总丰度与免疫治疗结局不一致。

核心结论

  • 9p21基因(MTAP、CDKN2A)缺失和NF2改变的间皮瘤免疫浸润组成可能不同。
  • 免疫浸润总丰度与免疫治疗结局不一致。
  • 未来免疫治疗生物标志物开发策略应考虑分子背景和间皮瘤肿瘤-免疫相互作用的功能特征。

研究设计与样本

  • 对胸膜和腹膜间皮瘤标本进行外显子组和转录组测序及多重免疫荧光,标注BAP1、CDKN2A、MTAP和NF2(merlin)状态。
  • 转录分析纳入113例间皮瘤标本(上皮样85例,非上皮样28例)。
  • 回顾性确定伊匹木单抗联合纳武利尤单抗的无进展生存和总生存。

主要发现

  • 113例标本分为四个预设肿瘤免疫微环境组:纤维化型14例、免疫荒漠型52例、免疫富集纤维化型13例、免疫富集非纤维化型34例。
  • BAP1改变肿瘤与BAP1野生型肿瘤的免疫浸润组成相似。
  • MTAP或CDKN2A缺失标本免疫细胞群普遍减少,以免疫荒漠表型为主。
  • NF2改变肿瘤中T淋巴细胞非显著性增加;多重免疫荧光显示merlin缺失间皮瘤T淋巴细胞浸润增加,包括调节性T细胞。
  • 接受伊匹木单抗联合纳武利尤单抗者中,BAP1改变患者生存改善,NF2和CDKN2A改变患者生存较短。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: First-line mesothelioma treatment paradigms prioritize histology without integrating molecular features. Findings from other thoracic cancers suggest that tumor immune microenvironment (TME) composition and immunotherapy efficacy are informed by genomic profile. Mesothelioma studies exploring the relationship between molecular alterations, immune infiltrate, and immunotherapy outcomes are needed. METHODS: Exome and transcriptomic sequencing and multiplex immunofluorescence were performed on pleural and peritoneal mesotheliomas annotated for BAP1, CDKN2A, MTAP, and NF2 (merlin) status to infer immune cell abundance and TME composition. Progression-free survival and overall survival on ipilimumab plus nivolumab was retrospectively determined according to molecular profile. RESULTS: Transcriptional analysis segregated 113 mesothelioma specimens (n = 85 epithelioid, n = 28 non-epithelioid) into the following four predefined TME groups: fibrotic (n = 14), immune desert (n = 52), immune-enriched fibrotic (n = 13), and immune-enriched nonfibrotic (n = 34). The composition of the immune infiltrate was similar when tumors with BAP1 alterations were compared with BAP1 wild-type tumors. In contrast, specimens with MTAP or CDKN2A loss had global decrease in immune populations with predominance of the immune desert phenotype. There was nonsignificant increase in T lymphocytes in NF2-altered tumors. Multiplex immunofluorescence similarly demonstrated increased T lymphoid infiltrate in mesotheliomas with merlin loss, including regulatory T cells. On ipilimumab plus nivolumab, patients with BAP1 alterations had improved survival whereas those with NF2 and CDKN2A alterations had shorter survival. CONCLUSIONS: Composition of the immune infiltrate may be distinct for mesotheliomas with loss of 9p21 genes (i.e., MTAP, CDKN2A) and NF2 alterations. Overall immune infiltrate abundance did not align with immunotherapy outcomes. Future immunotherapy biomarker development strategies should consider molecular background and functional characterization of mesothelioma tumor-immune interactions.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dagogo-Jack I, Mitchell O, Codd E, et al. Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol. 2025. PMID: 40578509. doi:10.1016/j.jtho.2025.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。